UPA CJC-1295 (With DAC) 2mg

UPA CJC-1295 (With DAC) is a self-mix peptide product containing a stated 2000mcg (2mg) of CJC-1295 with Drug Affinity Complex (DAC) per vial. CJC-1295 is a synthetic peptide developed to stimulate the body's natural release of growth hormone (GH) by acting on growth hormone-releasing hormone (GHRH) receptors.

The addition of Drug Affinity Complex (DAC) extends the peptide's activity by allowing it to bind to circulating albumin, resulting in a longer duration of action compared with shorter-acting GHRH analogues.

CJC-1295 has attracted research interest for its potential effects on growth hormone secretion, insulin-like growth factor 1 (IGF-1) levels, body composition and metabolic regulation. However, it remains an investigational peptide, and its safety and effectiveness for bodybuilding, anti-ageing or performance enhancement have not been established.

What UPA CJC-1295 Is Used For

CJC-1295 with DAC has been investigated for its ability to stimulate growth hormone secretion and influence the body's growth hormone-related signalling pathways.

Its primary research areas include:

• Growth Hormone Stimulation: Investigated for its ability to increase natural growth hormone secretion through activation of GHRH receptors.
• IGF-1 Regulation: Studied for its effects on circulating insulin-like growth factor 1 (IGF-1), a hormone involved in tissue growth and metabolism.
• Growth Hormone Signalling: Examined for its ability to produce sustained stimulation of the growth hormone axis.
• Body Composition: Has attracted research interest for potential effects on lean body mass and fat metabolism, although these benefits have not been clinically established.
• Muscle Tissue Maintenance: Investigated indirectly through the role of growth hormone and IGF-1 in protein metabolism and tissue maintenance.
• Metabolic Function: Studied for its influence on hormonal pathways involved in energy metabolism.
• Tissue Recovery: Has attracted interest for potential effects on tissue repair and recovery, although direct clinical evidence remains insufficient.
• Extended Hormonal Activity: Developed to maintain biological activity for longer periods through its albumin-binding properties.

These applications remain investigational, and CJC-1295 has not been established as a safe or effective treatment for muscle growth, fat loss or athletic performance enhancement.

How UPA CJC-1295 Works

CJC-1295 with DAC is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH), a naturally occurring hormone produced by the hypothalamus.

GHRH stimulates the pituitary gland to release growth hormone. CJC-1295 mimics this signalling process by binding to GHRH receptors on pituitary cells.

The Drug Affinity Complex (DAC) modification allows CJC-1295 to bind to circulating albumin, extending its presence in the bloodstream and prolonging its biological activity.

Its primary mechanisms include:

• GHRH Receptor Activation: Binds to growth hormone-releasing hormone receptors in the pituitary gland, stimulating growth hormone secretion.
• Growth Hormone Release: Encourages the pituitary gland to release endogenous growth hormone.
• IGF-1 Production: Increased growth hormone activity can stimulate the production of IGF-1, primarily in the liver.
• Albumin Binding: The DAC modification enables binding to circulating albumin, slowing the peptide's clearance from the bloodstream.
• Extended Duration of Action: Provides prolonged biological activity compared with shorter-acting GHRH analogues.
• Hormonal Signalling: Influences the growth hormone and IGF-1 axis, which is involved in metabolism, tissue development and cellular growth.
• Sustained GH and IGF-1 Elevation: Early human studies demonstrated prolonged increases in circulating growth hormone and IGF-1 following administration.

Although early clinical studies demonstrated hormonal activity, this does not establish the peptide's safety or effectiveness for bodybuilding, recovery, fat loss or anti-ageing purposes.

Possible Side Effects

CJC-1295 with DAC remains an investigational peptide with limited human clinical safety data. Its long-term effects, particularly those associated with sustained growth hormone and IGF-1 elevation, have not been fully established.

Common or Recognised Side Effects:

Reported reactions and potential safety concerns include:

• Injection-site redness, irritation or discomfort.
• Injection-site swelling.
• Headaches.
• Nausea or gastrointestinal discomfort.
• Flushing or temporary warmth.
• Dizziness or light-headedness.
• Increased heart rate or palpitations.
• Temporary changes in blood pressure.
• Fluid retention or swelling.
• Possible joint or muscle discomfort.